10-Q: Liquidia Q3 2025: YUTREPIA Drives Revenue Growth Amidst Legal Battles

Liquidia Corporation reports significant revenue growth driven by the commercial launch of YUTREPIA, alongside a reduced net loss, but faces ongoing patent and trade secret litigation and increased debt.

Summary

• Total revenue for the nine months ended September 30, 2025, surged to $66.299 million, a substantial increase from $11.079 million in the same period of 2024.
• Product sales from YUTREPIA, which began commercialization on June 2, 2025, accounted for $58.186 million of the total revenue for the nine months ended September 30, 2025.
• Net loss for the nine months ended September 30, 2025, decreased to $83.479 million, compared to $89.781 million in the prior year period.
• Selling, general and administrative expenses significantly increased by 80% to $108.942 million for the nine months ended September 30, 2025, primarily due to YUTREPIA commercialization efforts and legal fees.
• Research and development expenses decreased by 29% to $22.333 million for the nine months ended September 30, 2025, mainly due to a shift in personnel to commercial activities, partially offset by increased clinical expenses for the L606 program.
• Cash and cash equivalents stood at $157.496 million as of September 30, 2025, down from $176.479 million at December 31, 2024.
• Long-term debt, including current portion, increased to $192.497 million as of September 30, 2025, from $113.284 million at December 31, 2024, following additional funding from the HCR Agreement.
• An exclusive licensing agreement with Vectura Limited was signed on October 27, 2025, for L606 with Vectura's nebulizer device in the United States, involving an upfront payment of $2.0 million and potential milestone payments.

Sentiment

Score: 6

Explanation: The company achieved a significant milestone with YUTREPIA's FDA approval and commercial launch, leading to substantial revenue growth and a reduced net loss. However, this progress is overshadowed by multiple ongoing, high-stakes legal battles that could potentially remove YUTREPIA from the market. Increased cash burn and debt, along with challenges in the generic treprostinil market due to device availability, present notable headwinds. The L606 licensing agreement is a positive for the pipeline, but overall, the high legal uncertainty and financial commitments warrant a cautious outlook despite the commercial success.

Positives

• YUTREPIA received full FDA approval on May 23, 2025, for the treatment of both PAH and PH-ILD, and commercialization commenced on June 2, 2025.
• Product sales from YUTREPIA generated $58.186 million in revenue for the nine months ended September 30, 2025, establishing a new significant revenue stream.
• Net loss decreased to $83.479 million for the nine months ended September 30, 2025, from $89.781 million in the prior year, indicating improved financial performance.
• The company secured an additional $75.0 million in funding from the HCR Agreement during the nine months ended September 30, 2025.
• A new exclusive licensing agreement with Vectura Limited for L606 and its nebulizer device provides a clear path forward for this pipeline candidate.

Negatives

• Service revenue from the Sandoz Promotion Agreement decreased by $3.0 million for the nine months ended September 30, 2025, primarily due to lower sales volumes of generic treprostinil injection.
• Net cash used in operating activities increased to $79.930 million for the nine months ended September 30, 2025, compared to $72.609 million in the prior year, indicating higher cash burn.
• Total liabilities significantly increased to $253.929 million as of September 30, 2025, from $150.935 million at December 31, 2024, largely due to increased long-term debt.
• The company's accumulated deficit grew to $640.868 million as of September 30, 2025.
• The CADD-MS 3 infusion pump, necessary for subcutaneous administration of Sandoz's generic treprostinil injection, is no longer manufactured or supported by ICU Medical, constraining future sales of this product.

Risks

• United Therapeutics has initiated multiple lawsuits (327 Patent Litigation, 782 Patent Litigation, Trade Secret Litigation, Breach of Contract Litigation) against the company, seeking injunctive relief that could require YUTREPIA to be removed from the market and substantial monetary damages.
• The company is highly dependent on the success of YUTREPIA and L606, and these products may fail to maintain or receive final marketing approval or may not be commercialized successfully.
• Inability to manufacture sufficient quantities of products to meet commercial demand, especially given reliance on single-source suppliers for YUTREPIA's active ingredient, device, encapsulation, and packaging, and for L606's drug product and device.
• Significant competition from large pharmaceutical companies with greater resources, potentially leading to superior product profiles or earlier market entry for competing therapies.
• Future funding requirements are substantial, and additional financing may not be available on acceptable terms, if at all, potentially forcing delays or termination of development and commercialization efforts.
• The HCR Agreement contains operating and financial covenants, including a minimum cash balance of $15.0 million, and is subject to acceleration in specified circumstances, which could lead to HCR taking possession of collateral.
• Medical devices, not controlled by the company, are necessary for the administration of YUTREPIA, L606, and Treprostinil Injection, posing risks if manufacturers cease support or supply is disrupted.
• L606 is based on novel liposomal technology not previously approved by the FDA, making development time and cost, and regulatory approval, difficult to predict.
• Operations are concentrated in Morrisville, North Carolina, and interruptions due to natural disasters or unforeseen events could materially affect operations and may not be fully covered by insurance.
• The company will transition from a smaller reporting company to a large accelerated filer by December 31, 2025, increasing compliance costs and requiring significant time and effort.
• Exposure to claims and potential inability to obtain or maintain adequate product liability insurance.
• Adverse effects from public health emergencies, global economic uncertainty, geopolitical instability, and changes in trade policies or regulations (e.g., tariffs, drug pricing policies).

Future Outlook

The company expects to continue incurring significant expenses for YUTREPIA commercialization and L606 development. It believes current cash and cash equivalents are sufficient for at least the next twelve months, but acknowledges that sustained revenue from YUTREPIA is uncertain and additional financing may be required sooner than expected if revenues are insufficient. The company plans a pivotal study for L606 for PH-ILD and aims to expand its corporate infrastructure.

Management Comments

• We expect to continue to incur significant expenses as we commercialize YUTREPIA and advance our product candidates through clinical trials and seek regulatory approval of such product candidates.
• We believe we will have sufficient cash and cash equivalents to meet our financial obligations and minimum cash covenants for at least the next twelve months.
• While we have included anticipated cash inflows from YUTREPIA product sales in our projections, we may not be able to generate sustained revenue from YUTREPIA and the resources needed to support development of L606 may not be accurate.
• We have based our estimates on assumptions that may prove to be wrong, and we could be limited in our ability to continue to commercialize YUTREPIA and/or use our available capital resources sooner than we currently expect.

Industry Context

The biopharmaceutical industry for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) is highly competitive, with established players and emerging companies. Liquidia's YUTREPIA enters a market with existing inhaled treprostinil therapies like United Therapeutics' Tyvaso and Tyvaso DPI. The generic treprostinil market is also competitive, with prices often declining with new entrants. Regulatory changes, such as the Inflation Reduction Act, are increasing scrutiny on drug pricing and could impact profitability across the industry.

Comparison to Industry Standards

• YUTREPIA competes with United Therapeutics' Tyvaso (approved for PAH since 2009, PH-ILD since 2021) and Tyvaso DPI (approved for PAH and PH-ILD in May 2022).
• Insmed's TPIP, a dry-powder treprostinil prodrug, is in Phase 3 development for PH-ILD and planned for PAH, potentially offering once-daily dosing which could be a competitive advantage over YUTREPIA and Tyvaso DPI.
• Other inhaled prostacyclin analog therapies include Actelion's Ventavis (iloprost), approved for PAH since 2004.
• The company also faces competition from other treprostinil-based drugs like United Therapeutics' Orenitram (oral) and Remodulin (parenteral).
• The generic treprostinil for parenteral administration market includes Sandoz's product (promoted by Liquidia), Teva Pharmaceutical Industries Ltd., Par Pharmaceutical, Inc., Dr. Reddys Laboratories Inc., and Alembic, leading to increased price competition.
• Broader competition exists from other classes of therapeutic agents for PAH and/or PH-ILD, including IP-agonists (selexipag, ralinepeg), Endothelin receptor antagonists (bosentan, macitentan, ambrisentan), PDE-5 inhibitors (tadalafil, sildenafil), sGC stimulators (riociguat, mosliciguat), and Activin signaling inhibitors (Merck & Co.'s sotatercept/Winrevair, approved March 2024).

Legal Proceedings

• 327 Patent Litigation: United Therapeutics alleges infringement of U.S. Patent No. 11,826,327 by YUTREPIA (PH-ILD indication). Trial held June 2025, decision pending. United Therapeutics seeks injunctive relief to remove YUTREPIA from the market and monetary damages.
• 782 Patent Litigation: United Therapeutics alleges infringement of U.S. Patent No. 11,357,782 by YUTREPIA. Preliminary injunction denied May 2025. Motion to dismiss/stay pending, hearing scheduled November 2025. United Therapeutics seeks injunctive relief and monetary damages.
• Trade Secret Litigation: United Therapeutics alleges misappropriation of trade secrets and unfair trade practices by the company and a former employee. Motions for summary judgment denied. Trial date not yet set. United Therapeutics seeks injunctive relief and monetary damages.
• Breach of Contract Litigation: United Therapeutics alleges a former employee breached employment agreements by not assigning patent interests, claiming ownership interest in company patents, including the 494 Patent. Motion to dismiss denied May 2025, company is appealing.
• 494 Patent Litigation: The company filed a complaint against United Therapeutics for infringement of U.S. Patent No. 10,898,494 by Tyvaso DPI. Motion to dismiss or stay pending, hearing scheduled November 2025.
• RareGen Litigation: Sandoz and Liquidia PAH sued United Therapeutics and Smiths Medical for antitrust violations and breach of settlement. Partial summary judgment granted to Sandoz on breach of contract, resulting in a $70.6 million judgment in November 2024. All parties have appealed, with oral argument scheduled for November 2025.

Related Party Transactions

• PBM RG Holdings, LLC, a related party controlled by a major stockholder and board member, is involved in a Litigation Funding and Indemnification Agreement, reimbursing litigation expenses not covered by Henderson and receiving certain litigation proceeds.
• A fund affiliated with Paul B. Manning, a board member, purchased approximately $3.0 million in common stock in the September 2024 public offering.
• Funds managed by Caligan Partners LP, the largest stockholder, purchased approximately $10.0 million in common stock in a private placement concurrent with the September 2024 offering.

Stakeholder Impact

• Shareholders face significant potential share price volatility due to the outcome of ongoing legal proceedings, which could materially impact YUTREPIA's commercialization.
• Patients with PAH and PH-ILD benefit from the availability of YUTREPIA as a new treatment option, with L606 offering future potential, but access to generic treprostinil injection is constrained by device availability.
• Employees are impacted by increased headcount for commercialization efforts, but the company faces risks in retaining skilled personnel.
• Creditors, particularly HCR, have provided significant financing but impose covenants that restrict business activities and carry acceleration risk.
• Customers, including specialty pharmacies and distributors, have a new product (YUTREPIA) to market, but face challenges with the supply of medical devices for generic treprostinil injection.

Next Steps

• Continue commercialization of YUTREPIA for PAH and PH-ILD.
• Advance L606 through clinical trials, including a planned pivotal study for the treatment of PH-ILD.
• Seek regulatory approval for L606.
• Expand corporate infrastructure to support commercial activities.
• Identify, develop, and obtain FDA 510(k) clearance for new infusion pumps to replace the CADD-MS 3 for subcutaneous Treprostinil Injection.
• Establish a secondary supply chain for L606 outside of Taiwan.
• Conduct a post-marketing clinical study for YUTREPIA in pediatric patients.

Key Dates

Recommendation

While Liquidia has achieved a significant milestone with the FDA approval and commercial launch of YUTREPIA, leading to substantial revenue growth and a reduced net loss, the company faces critical, ongoing legal challenges with United Therapeutics. The pending decision in the 327 Patent Litigation, which could result in an injunction requiring YUTREPIA's removal from the market, represents an existential risk. Additionally, increased cash burn, rising debt, and supply chain dependencies for key products introduce considerable uncertainty. The L606 licensing agreement is a positive pipeline development, but its commercial impact is long-term. Given the high-risk, high-reward profile and the immediate, material legal overhang, a 'hold' recommendation is prudent for seasoned investors, awaiting clarity on the litigation outcomes before making a more definitive investment decision.

Keywords

YUTREPIA, Pulmonary Arterial Hypertension, PH-ILD, Treprostinil, L606, Biopharmaceutical, SEC Filing, 10-Q, Patent Litigation, FDA Approval, Commercialization, Rare Disease, Drug Development, Financial Results